Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexocee is a generic oral potassium supplement developed and manufactured by Bini Laboratories Pvt. Ltd., an Indian pharmaceutical company. It is primarily indicated for the treatment and prevention of hypokalemia, a condition characterized by abnormally low levels of potassium in the blood. As an essential mineral and systemic electrolyte, potassium is critical for maintaining intracellular osmotic pressure, nerve impulse transmission, and muscle contraction (including cardiac, skeletal, and smooth muscle). Dexocee is used to replenish potassium levels in patients where dietary intake is insufficient or where losses are excessive, such as during diuretic therapy or certain renal conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dexocee.